Monte Rosa Therapeutics

Monte Rosa Therapeutics published groundbreaking research on the cover of Science magazine, demonstrating how their AI and machine learning technologies have dramatically expanded the targetable protein space for molecular glue degraders.

Monte Rosa Therapeutics received FDA clearance for its Investigational New Drug application for MRT-8102, a NEK7-directed molecular glue degrader targeting inflammatory diseases driven by NLRP3 inflammasome and IL-1β dysregulation.

Monte Rosa Therapeutics presented preclinical data at AACR 2025 showing their CDK2-directed molecular glue degrader MRT-51443 achieved superior tumor regression compared to standard care in HR-positive/HER2-negative breast cancer models.

Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases.

• Monte Rosa Therapeutics anticipates Q1 2025 clinical data from its Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader for immune-mediated conditions. • The company expects to share additional Phase 1/2 results for MRT-2359 in Q1 2025, which targets MYC-driven solid tumors and has shown a favorable safety profile. • An IND application for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases, is on track for submission in the first half of 2025. • Monte Rosa's strong cash position, with $377 million expected as of December 31, 2024, is projected to fund operations into 2028.

• The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions. • NLRP3 inhibitors are being explored for treating neurodegenerative diseases like Alzheimer’s and Parkinson’s, as well as metabolic conditions such as NASH. • Clinical trials are underway, with companies like Novo Nordisk and NodThera reporting positive data on their NLRP3 inhibitor candidates. • Collaborations, such as the one between Halia Therapeutics and Biolexis Therapeutics, are advancing the development of brain-penetrant NLRP3 inhibitors for neuroinflammation.

• Monte Rosa Therapeutics and Novartis have entered an exclusive agreement to develop and commercialize VAV1 molecular glue degraders, including MRT-6160. • Novartis will gain worldwide rights for MRT-6160 development, manufacturing, and commercialization, commencing with Phase 2 studies, while Monte Rosa completes Phase 1. • MRT-6160, an orally bioavailable VAV1 degrader, has shown promise in preclinical models for various immune-mediated conditions by decreasing linked cytokines. • The agreement includes a $150 million upfront payment to Monte Rosa, with potential milestones reaching $2.1 billion, plus royalties on ex-U.S. sales.

• Novartis and Monte Rosa Therapeutics have entered into a global agreement to develop and commercialize VAV1 molecular glue degraders, including MRT-6160. • Monte Rosa will receive $150 million upfront and is eligible for up to $2.1 billion in milestone payments, plus royalties on ex-U.S. net sales. • MRT-6160, an orally bioavailable VAV1 degrader, is currently in Phase I trials for immune-mediated conditions and will transition to Novartis for Phase II development. • The collaboration aims to leverage molecular glue degraders to target proteins previously considered undruggable, offering new therapeutic options.

Novartis and Monte Rosa Therapeutics have entered into a global licensing agreement worth up to $2.1 billion to develop VAV1-directed molecular glue degraders.

• Monte Rosa Therapeutics and Novartis AG have entered into a collaboration to develop molecular glue degraders (MGDs) targeting VAV1. • The deal includes MRT-6160, a phase I asset being studied in healthy volunteers for immune-mediated conditions, and is valued at $2.1 billion. • This collaboration aims to advance VAV1 MGDs for immune-mediated diseases, leveraging Monte Rosa's QuEEN platform and Novartis' expertise.